Cherry Ma focuses her practice on corporate finance and capital markets. Cherry advises clients on Hong Kong initial public offerings, mergers and acquisitions, regulatory compliance, and general corporate matters.
CICC, CCB, CMB, CMS and other underwriters in the approximately US$150 million IPO of Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) on the Hong Kong Stock Exchange
Sipai Health Technology Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
3D Medicines Inc. in its US$52 million IPO and listing on the Hong Kong Stock Exchange
China VAST Industrial Urban Development (6166.HK) and its controlling shareholder, Profit East Limited, in the US$285 million all-cash take private proposal by China Jinmao Holdings Group Limited (817.HK)